The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer

Abstract excerpt

In a study recently published in Nature Medicine , Lu et al. examined the feasibility and safety of using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-engineered, patient-derived T cells to treat late-stage lung cancer. 1

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to CRISPR and Genetic Engineering
• Share to Pluripotent Stem Cells Research